Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
AssigneeSutro Biopharma, Inc.
InventorsKalyani PENTA, Ryan STAFFORD, Avinash GILL, Xiaofan LI, Alice YAM, Christopher THANOS, Aaron SATO
Life of this patent
Estimating the term…
Abstract
Provided herein are antibodies that selectively bind to CD74 and its isoforms and homologs, and compositions comprising the antibodies. Also provided are methods of using the antibodies, such as therapeutic and diagnostic methods.
Claims70
An isolated antibody that specifically binds to CD74, wherein the antibody comprises a CDR-H3 sequence defined by the consensus sequence G-G-α3-α4-α5-α6-α7-α8-α9-α10-G-α12-D-V, wherein:
- a. α3 is T, S, Q, M, or A;
- b. α4 is R, L, or V;
- c. α5 is V, E, A, G, I, D, or M;
- d. α6 is R, L, H, G, Q, or T;
- e. α7 is G or R;
- f. α8 is A, L, E, or G;
- g. α9 is V, I, M, F, R, or L;
- h. α10 is Y, H, F, or S;
- and
- i. α12 is T, L, H, or N,
- wherein if α9 is M, then either α3 is not T, α4 is not L, α5 is not V, α6 is not R, α7 is not G, α8 is not A, α10 is not Y, α12 is not T, or combinations thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
An isolated antibody that specifically binds to CD74, wherein the antibody comprises a CDR-H2 sequence defined by the consensus sequence V-σ2-W-σ4-D-σ6-S-σ8-σ9-σ10-Y-A-σ13-S-V-K-G, wherein:
- a. σ2 is I, T, or V;
- b. σ4 is Y, D, or H;
- c. σ6 is G or A;
- d. σ8 is N, I, D, H, K, or R;
- e. σ9 is K, E, R, S, T, or D;
- f. σ10 is Y, I, V, K, or N;
- and
- g. σ13 is D or G,
- wherein if σ2 is I, then either σ4 is not Y, α6 is not G, α8 is not N, σ9 is not K, σ10 is not Y, σ13 is not D, or combinations thereof.
(canceled)
An isolated antibody that specifically binds to CD74, wherein the antibody comprises a CDR-L3 sequence defined by the consensus sequence Q-Q-Y-φ4-φ5-Y-P-L-T, wherein:
- a. φ4 is N, H, or Y;
- and
- b. φ5 is S, T, I, L, Y, or A,
- wherein if φ5 is S, then φ4 is not N.
(canceled)
An isolated antibody that specifically binds to CD74, wherein the antibody comprises a CDR-H3 sequence selected from SEQ ID NOs:
- 130-157, or a variant thereof having zero or one amino acid substitution.
(canceled)
An isolated antibody that specifically binds to CD74, wherein the antibody comprises:
- a. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 1 and 33;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 65 and 97;
- and a CDR-H3 comprising SEQ ID NO:
- 129;
- b. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 2 and 34;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 66 and 98;
- and a CDR-H3 comprising SEQ ID NO:
- 130;
- c. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 3 and 35;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 67 and 99;
- and a CDR-H3 comprising SEQ ID NO:
- 131;
- d. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 4 and 36;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 68 and 100;
- and a CDR-H3 comprising SEQ ID NO:
- 132;
- e. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 5 and 37;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 69 and 101;
- and a CDR-H3 comprising SEQ ID NO:
- 133;
- f. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 6 and 38;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 70 and 102;
- and a CDR-H3 comprising SEQ ID NO:
- 134;
- g. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 7 and 39;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 71 and 103;
- and a CDR-H3 comprising SEQ ID NO:
- 135;
- h. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 8 and 40;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 72 and 104;
- and a CDR-H3 comprising SEQ ID NO:
- 136;
- i. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 9 and 41;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 73 and 105;
- and a CDR-H3 comprising SEQ ID NO:
- 137;
- j. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 10 and 42;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 74 and 106;
- and a CDR-H3 comprising SEQ ID NO:
- 138;
- k. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 11 and 43;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 75 and 107;
- and a CDR-H3 comprising SEQ ID NO:
- 139;
- l. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 12 and 44;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 76 and 108;
- and a CDR-H3 comprising SEQ ID NO:
- 140;
- m. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 13 and 45;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 77 and 109;
- and a CDR-H3 comprising SEQ ID NO:
- 141;
- n. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 14 and 46;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 78 and 110;
- and a CDR-H3 comprising SEQ ID NO:
- 142;
- o. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 15 and 47;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 79 and 111;
- and a CDR-H3 comprising SEQ ID NO:
- 143;
- p. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 16 and 48;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 80 and 112;
- and a CDR-H3 comprising SEQ ID NO:
- 144;
- q. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 17 and 49;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 81 and 113;
- and a CDR-H3 comprising SEQ ID NO:
- 145;
- r. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 18 and 50;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 82 and 114;
- and a CDR-H3 comprising SEQ ID NO:
- 146;
- s. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 19 and 51;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 83 and 115;
- and a CDR-H3 comprising SEQ ID NO:
- 147;
- t. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 20 and 52;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 84 and 116;
- and a CDR-H3 comprising SEQ ID NO:
- 148;
- u. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 21 and 53;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 85 and 117;
- and a CDR-H3 comprising SEQ ID NO:
- 149;
- v. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 22 and 54;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 86 and 118;
- and a CDR-H3 comprising SEQ ID NO:
- 150;
- w. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 23 and 55;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 87 and 119;
- and a CDR-H3 comprising SEQ ID NO:
- 151;
- x. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 24 and 56;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 88 and 120;
- and a CDR-H3 comprising SEQ ID NO:
- 152;
- y. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 25 and 57;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 89 and 121;
- and a CDR-H3 comprising SEQ ID NO:
- 153;
- z. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 26 and 58;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 90 and 122;
- and a CDR-H3 comprising SEQ ID NO:
- 154;
- aa. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 27 and 59;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 91 and 123;
- and a CDR-H3 comprising SEQ ID NO:
- 155;
- or
- bb. a VH comprising:
- a CDR-H1 comprising at least one of SEQ ID NOs:
- 28 and 60;
- a CDR-H2 comprising at least one of SEQ ID NOs:
- 92 and 124;
- and a CDR-H3 comprising SEQ ID NO:
- 156.
An isolated antibody that specifically binds to CD74, wherein the antibody comprises a VH region selected from SEQ ID NOs:
- 230-251 and 273-280, or a variant thereof having seven or fewer amino acid substitutions, wherein the substitutions are conservative amino acid substitutions.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.